AUA 2020: Neoadjuvant Apalutamide + Prednisone With or Without Abiraterone/Prednisone Shows Promise in Facilitating Nerve-Sparing Radical Prostatectomy in High-Risk Prostate Cancer

ARTICLES

AUA 2020: Neoadjuvant Apalutamide + Prednisone With or Without Abiraterone/Prednisone Shows Promise in Facilitating Nerve-Sparing Radical Prostatectomy in High-Risk Prostate Cancer

PRACTICE UPDATE

PUBLISHED: 18 MAY 2020

In high-risk prostate cancer, apalutamide-based neoadjuvant therapy prior to radical prostatectomy has been shown to result in reduction of tumor volume and trends in support of increased potency preservation without an adverse effect on rates of positive surgical margins.